Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Aug;64(2):345–348. doi: 10.1038/bjc.1991.303

The roles of age and sex in the prognosis of chronic leukaemias. A study of 373 cases.

B Jaksić 1, B Vitale 1, E Hauptmann 1, A Planinc-Peraica 1, S Ostojic 1, R Kusec 1
PMCID: PMC1977541  PMID: 1892761

Abstract

The roles of age and sex and their relationship to other prognostic factors were studied in 117 chronic myeloid leukaemia (CML) and in 256 chronic lymphocytic leukaemia (CLL) patients. Survival in CML was not related either to age at diagnosis or to sex. In contrast, the CLL patients classified into four age strata (less than 50, 50-59, 60-69, greater than 70 years) had an expected median survival (EMS) of 142, 101, 85 and 33 months respectively (chi 2 for heterogeneity = 35.59, P less than 0.0005; chi 2 for trend = 25.09, P less than 0.0005). Prognostic power was independent of sex, Rai stages, total tumour mass score (TTM), TTM distribution pattern, anaemia, thrombocytopenia, serum immunoglobulins and response to therapy. The relative survival rate (the ratio of patient's EMS and EMS in age- and sex-matched general population) was 0.40 in CLL patients and 0.13 in CML patients. Relative survival was more reduced in older CLL patients than in younger ones (0.37 vs 0.47, respectively), whereas relative survival was less reduced in older CML patients than in younger ones (0.18 vs 0.12, respectively). The results show that the age is a significant independent prognostic factor in CLL but not in CML. The difference in the effects of age on prognosis in CLL and CML most probably reflects the fundamental differences in their respective pathogeneses.

Full text

PDF
345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernadou A., Bernard J., Bilski-Pasquier G., Bousser J. A propos du pronostic des leucémies lymphoïdes chroniques. Ann Med Interne (Paris) 1973 Aug-Sep;124(8):549–560. [PubMed] [Google Scholar]
  2. Binet J. L., Leporrier M., Dighiero G., Charron D., D'Athis P., Vaugier G., Beral H. M., Natali J. C., Raphael M., Nizet B. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977 Aug;40(2):855–864. doi: 10.1002/1097-0142(197708)40:2<855::aid-cncr2820400239>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  3. Boggs D. R., Sofferman S. A., Wintrobe M. M., Cartwright G. E. Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med. 1966 Feb;40(2):243–254. doi: 10.1016/0002-9343(66)90105-7. [DOI] [PubMed] [Google Scholar]
  4. Catovsky D., Fooks J., Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1989 Jun;72(2):141–149. doi: 10.1111/j.1365-2141.1989.tb07674.x. [DOI] [PubMed] [Google Scholar]
  5. Galton D. A. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J. 1966 May 7;94(19):1005–1010. [PMC free article] [PubMed] [Google Scholar]
  6. Kantarjian H. M., Talpaz M., Gutterman J. U. Chronic myelogenous leukemia--past, present, and future. Hematol Pathol. 1988;2(2):91–120. [PubMed] [Google Scholar]
  7. OSGOOD E. E. TREATMENT OF CHRONIC LEUKEMIAS. J Nucl Med. 1964 Feb;5:139–153. [PubMed] [Google Scholar]
  8. Paolino W., Infelise V., Levis A., Marmont F., Vitolo U., Paolino F., Rossi M., Jayme A., Remondino M. Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases. Cancer. 1984 Jul 15;54(2):339–346. doi: 10.1002/1097-0142(19840715)54:2<339::aid-cncr2820540227>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  10. Silver R. T., Mick R., Cooper R., Ellison R. R., Levy R., Brunner K., Schwartz J. M., Holland J. F. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. Cancer. 1987 Oct 1;60(7):1442–1448. doi: 10.1002/1097-0142(19871001)60:7<1442::aid-cncr2820600706>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  11. Talpaz M., Kantarjian H. M., Kurzrock R., Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol. 1988 Jan;25(1):62–73. [PubMed] [Google Scholar]
  12. Tura S., Baccarani M., Corbelli G. Staging of chronic myeloid leukaemia. Br J Haematol. 1981 Jan;47(1):105–119. doi: 10.1111/j.1365-2141.1981.tb02765.x. [DOI] [PubMed] [Google Scholar]
  13. Zippin C., Cutler S. J., Reeves W. J., Jr, Lum D. Survival in chronic lymphocytic leukemia. Blood. 1973 Sep;42(3):367–376. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES